SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-303183
Filing Date
2022-12-13
Accepted
2022-12-13 06:09:44
Documents
12
Period of Report
2022-12-12
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d425649d8k.htm   iXBRL 8-K 30471
  Complete submission text file 0001193125-22-303183.txt   153327

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA clvs-20221212.xsd EX-101.SCH 2873
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20221212_lab.xml EX-101.LAB 17996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20221212_pre.xml EX-101.PRE 11277
6 EXTRACTED XBRL INSTANCE DOCUMENT d425649d8k_htm.xml XML 3350
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 221458483
SIC: 2834 Pharmaceutical Preparations